# Joel W. Neal

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/joel-w-neal/

## Facts

| Field | Value |
| --- | --- |
| Citations | 20,338 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 56 |
| i10-index | 174 |
| Last Known Institution | Palo Alto Institute |
| OpenAlex ID | https://openalex.org/A5034377849 |
| ORCID iD | https://orcid.org/0000-0003-3119-9334 |
| Works | 601 |

## Researcher papers

- [An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage](https://scholariq.org/papers/an-ultrasensitive-method-for-quantitating-circulating-tumor-dna-with-broad/)
- [Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry](https://scholariq.org/papers/immune-checkpoint-inhibitors-for-patients-with-advanced-lung-cancer-and/)
- [Integrated digital error suppression for improved detection of circulating tumor DNA](https://scholariq.org/papers/integrated-digital-error-suppression-for-improved-detection-of-circulating-tumor/)
- [Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling](https://scholariq.org/papers/early-detection-of-molecular-residual-disease-in-localized-lung-cancer-by/)
- [Integrating genomic features for non-invasive early lung cancer detection](https://scholariq.org/papers/integrating-genomic-features-for-non-invasive-early-lung-cancer-detection/)
- [Rociletinib in <i>EGFR</i>-Mutated Non–Small-Cell Lung Cancer](https://scholariq.org/papers/rociletinib-in-i-egfr-i-mutated-non-small-cell-lung-cancer/)
- [Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients](https://scholariq.org/papers/circulating-tumour-dna-profiling-reveals-heterogeneity-of-egfr-inhibitor/)
- [<i>EGFR</i> -Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes](https://scholariq.org/papers/i-egfr-i-mutant-adenocarcinomas-that-transform-to-small-cell-lung-cancer-and/)
- [Heterogeneity Underlies the Emergence of <i>EGFR</i> T790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor](https://scholariq.org/papers/heterogeneity-underlies-the-emergence-of-i-egfr-i-t790-wild-type-clones/)
- [Targeting RET in Patients With <i>RET</i>-Rearranged Lung Cancers: Results From the Global, Multicenter <i>RET</i> Registry](https://scholariq.org/papers/targeting-ret-in-patients-with-i-ret-i-rearranged-lung-cancers-results-from-the/)
- [A vision–language foundation model for precision oncology](https://scholariq.org/papers/a-vision-language-foundation-model-for-precision-oncology/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Palo Alto Institute](https://scholariq.org/institutions/palo-alto-institute/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.